Intrapatient

2001, Matthew Miller, “Phase I Oncology Trials”, chapter 10-13 of Robert J. Amdur and Elizabeth A. Bankert (editors), Institutional Review Board: Management and Function, Jones & Bartlett Publishers, →ISBN, page 470, Intrapatient dose escalation is chosen as an example of innovative dosing strategies because it is precisely the proscription of individualized (i.e., within-patient) dose adjustments that most clearly demonstrated to my patients how research interests trump their medical interests.